Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

10 Sep 2010

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer.

10 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

Non-invasive test using patient's breath can detect cancer

A test using a patient's breath could be developed to detect lung, breast, bowel and prostate cancers, a team of scientists have discovered.While these results are only preliminary, the study published in the British Journal of Cancer today (Wednesday), found that sensors could distinguish between the breath of healthy patients and those who have cancer.

9 Sep 2010

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

EDAP TMS SA, the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU.

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

AHRQ releases free evidence-based guides for eight health conditions

HHS' Agency for Healthcare Research and Quality today released a series of free evidence-based guides designed to help Spanish speakers understand and compare the risks, benefits and side effects of treatments for eight health conditions.

7 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

Protagen AG announces € 10.0 Million for second round of finance totaling

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis announced today a second round of finance totalling a volume of € 10.0 Million.

7 Sep 2010

CyberKnife radiosurgery treatment effective for prostate cancer without side effects

CyberKnife radiosurgery treatment for prostate cancer is rapid, effective and has no side effects, with the added benefit of being non-invasive.

3 Sep 2010

More support needed for erectile dysfunction says sexologist

According to sexologist Bettina Arndt, there are thousands of Australian men with erectile dysfunction who are sexually impotent because of their condition and the lack of affordable treatments. Arndt said that funds distribution for breast prostheses for female cancer patients is one of the examples of mismatches in funding.

3 Sep 2010

Virginia G. Piper Cancer Center at Scottsdale Healthcare offers free prostate cancer screenings

Recognizing that early detection can save lives, the Virginia G. Piper Cancer Center at Scottsdale Healthcare is offering free prostate cancer screenings from 8:30 a.m.-12 p.m. on Saturday, Sept. 11.

3 Sep 2010

President Obama designates September 2010 as National Prostate Cancer Awareness Month

On August 31, President Barack Obama signed a presidential proclamation designating September 2010 as 'National Prostate Cancer Awareness Month," stating: "Until we find a cure for this disease, my Administration will continue promoting awareness of this illness and supporting prostate cancer research and treatment."

3 Sep 2010

New study finds additional link between Light At Night and cancer

A new study from the Center for Interdisciplinary Chronobiological Research at the University of Haifa has found an additional link between Light At Night (LAN) and cancer. This research joins a series of earlier studies carried out at the University of Haifa that also established the correlation. "High power light bulbs contribute more to 'environmental light pollution', which the study has shown is a carcinogenic pollution," notes Prof. Abraham Haim, who headed the study.

3 Sep 2010

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.

3 Sep 2010

SET the PACE conducts annual race to raise prostate cancer awareness

Too many men don't know their risk for developing prostate cancer, a disease that currently affects more than two million American men. In fact, according to a recent report, 61 percent of men only know "a little" and an additional 20 percent say they know nothing about prostate health. This knowledge gap is of critical importance given that one in six men has a lifetime risk of developing prostate cancer.

2 Sep 2010

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.

31 Aug 2010

Ipsen 2010 first half revenue increases to €31.7 million

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on August 30, 2010 to review the Group's results for the first half 2010, published today

31 Aug 2010

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

Elbit Imaging Ltd. that it's subsidiary, InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.

31 Aug 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Nucletron to present innovative cancer treatment during ESTRO29

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Non-invasive test using patient's breath can detect cancer

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

AHRQ releases free evidence-based guides for eight health conditions

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Protagen AG announces € 10.0 Million for second round of finance totaling

CyberKnife radiosurgery treatment effective for prostate cancer without side effects

More support needed for erectile dysfunction says sexologist

Virginia G. Piper Cancer Center at Scottsdale Healthcare offers free prostate cancer screenings

President Obama designates September 2010 as National Prostate Cancer Awareness Month

New study finds additional link between Light At Night and cancer

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

SET the PACE conducts annual race to raise prostate cancer awareness

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

Ipsen 2010 first half revenue increases to €31.7 million

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in